PMID- 38115370
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20231223
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 50
DP  - 2023 Dec 15
TI  - Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A 
      single center long term experience.
PG  - e36435
LID - 10.1097/MD.0000000000036435 [doi]
LID - e36435
AB  - This study examined the effects of regorafenib (Reg) on progression-free survival 
      (PFS), overall survival (OS), and adverse events (AEs) in metastatic colorectal 
      cancer (mCRC) patients who underwent targeted treatment and chemotherapy. Reg was 
      administered as a third-line treatment to 84 patients who had undergone 2 rounds 
      of chemotherapy and targeted therapy and subsequently experienced progression. 
      Treatment was initiated with a daily dose of 80 or 120 mg, based on the patient's 
      ability to tolerate the medication, which was increased to 160 mg/day. The median 
      PFS with Reg was 4 +/- 0.2 months, while the median OS was 9 +/- 1.2 months. When 
      compared to patients who started Reg treatment at 80 mg, patients starting at 
      160 mg had longer median PFS and OS (PFS:6 +/- 2.1 months vs 4 +/- 0.2 months; 
      P = .05; OS:13 +/- 0.7 months vs 6 +/- 1.3 months; P = .069). Patients with 
      right-sided colon cancer who received Reg as third-line therapy had a 
      significantly longer mPFS than those with left-sided colon cancer (8 months +/- 4 
      vs 4 months +/- 0.3, P = .039). Patients with KRAS mutations had a prolonged mPFS 
      than those with panRAS-wild type (6 +/- 1.6 months vs 4 +/- 0.3 months, P = .06). The 
      mPFS contribution in the BRAF mutant subgroup with poor prognosis is promising, 
      as it is similar to that of patients without BRAF mutations (4 months +/- 0.8 x 4 
      months +/- 0.5, P = .74). The most common AEs reported were elevated liver enzyme 
      levels and dermatological toxicities.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Ozkan, Merve
AU  - Ozkan M
AUID- ORCID: 0000-0002-2202-5159
AD  - Izmir Katip Celebi University, Department of Medical Oncology, Izmir, Turkey.
FAU - Oflazoglu, Utku
AU  - Oflazoglu U
FAU - Yildiz, Yasar
AU  - Yildiz Y
FAU - Guc, Zeynep G
AU  - Guc ZG
FAU - Salman, Tarik
AU  - Salman T
FAU - Unal, Sinan
AU  - Unal S
FAU - Kucukzeybek, Yuksel
AU  - Kucukzeybek Y
FAU - Alacacioglu, Ahmet
AU  - Alacacioglu A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 24T2A1DOYB (regorafenib)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Humans
MH  - *Colorectal Neoplasms/pathology
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Colonic Neoplasms/drug therapy
PMC - PMC10727636
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/12/20 06:42
MHDA- 2023/12/21 06:43
PMCR- 2023/12/15
CRDT- 2023/12/20 01:02
PHST- 2023/12/21 06:43 [medline]
PHST- 2023/12/20 06:42 [pubmed]
PHST- 2023/12/20 01:02 [entrez]
PHST- 2023/12/15 00:00 [pmc-release]
AID - 00005792-202312150-00131 [pii]
AID - 10.1097/MD.0000000000036435 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Dec 15;102(50):e36435. doi: 
      10.1097/MD.0000000000036435.